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Elucidation of genetic alterations is an approach to understanding the underlying molecular mechanisms of progression of
human prostate cancers. We have searched for genes differentially expressed in advanced prostate cancers using cDNA-
representational difference analysis, and thereby isolated the Lsm1 as one of down-regulated gene. An Lsm1 expression vector
was transfected into PC3 cells, normally featuring down-regulated Lsm1, and four transfectants were established. No
differences in morphology or cell proliferation were evident in comparison with parent PC3 or PC3/mock-transfectants. In
contrast, signiﬁcant suppression of invasive potential or metastatic ability of Lsm1 transfectants was observed in the Matrigel
chemoinvasion assay and in nude mice, respectively. With human prostate cancers, almost all of informative prostatectomised
cases without neoadjuvant therapy showed allelic retention in the Lsm1 region, whereas refractory cancers frequently showed
allelic loss in this region. No critical gene mutations were found in open reading frame of Lsm1 in prostate cancers examined
by PCR–SSCP analysis, including localised and refractory cancers. These results suggest that Lsm1 is deeply involved in
prostate cancer progression through its down-regulation, independent of any gene mutation.
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Prostate cancer has become the most common malignancy in men
in western countries (Pisani et al, 1993) and while the incidence
and mortality from this cause in Japan are much lower, they
appear to be rapidly increasing (Hsing et al, 2000). Androgen abla-
tion therapy is generally accepted for prostate cancer. However, the
outgrowth of androgen-independent cancer cells is a frequent
outcome, eventually lead to the patient’s death. Therefore, under-
standing of the molecular mechanisms of the acquisition of
metastatic potential or the androgen-independent phenotype of
tumour cells is urgently needed.
Several molecular cytogenetic studies have demonstrated that
interstitial deletions of chromosomes 5q, 6q, 7q, 8p, 10p, 10q,
13q, 16q, 17p, 17q, and 18q are the most prevalent changes in
human prostate cancers (Latil and Lidereau, 1998; Brothman et
al, 1999; Verma et al, 1999; Ozen and Pathak, 2000), suggesting
the presence of tumour suppressor genes in these regions. In parti-
cular, loss of heterozygosity (LOH) at chromosome 8p has been
found in a majority of prostate cancers.
We examined the genes differentially expressed in advanced
prostate cancers using cDNA-representational difference analysis
(RDA), which is an efﬁcient and reliable technique to isolate genes
differentially expressed between samples to be compared (Hubank
and Schatz, 1994), and thereby isolated the Lsm1 gene as one of
them. The Lsm1 gene was mapped to 8p11.2, a region which is
frequently deleted in prostate cancers, using BLAST search program
and down-regulation shown for refractory cancer and androgen-
independent DU145 and PC3 cells. The data prompted the present
examination of whether Lsm1 is a target gene involved in the
acquisition of androgen-independence or the metastatic phenotype
in human prostate cancers.
MATERIALS AND METHODS
Samples
Normal prostate and organ-conﬁned prostate cancers were
obtained from patients who underwent total cystoprostatectomy
or prostatectomy for bladder or prostate cancer. None of these
cancer patients had previously undergone chemotherapy, radiother-
apy or hormonal therapy. Refractory prostate cancers were
obtained from autopsy cases who died of the disease. All autopsy
cases had undergone hormonal therapy using anti-androgens,
LH–RH-agonist or castration. Human prostate cancer cell lines,
DU145, LNCaP and PC3, were purchased from the American Type
Culture Collection. For cDNA–RDA, localised prostate cancer
(moderately differentiated adenocarcinoma, Gleason’s score:
3+4=7) and refractory cancer (poorly differentiated adenocarcino-
ma, Gleason’s score: 5+5=10) were used.
cDNA–RDA
cDNA was synthesised by using molony murine leukemia virus
reverse transcriptase (Gibco – BRL) with oligo-d(T) primers.
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cations as previously described (Ushijima et al, 1997). Brieﬂy,
to prepare representations (amplicons), 5 mg aliquots of
double-stranded cDNA were digested with Sau3AI (Toyobo
Biochemicals, Osaka, Japan), phenol extracted and ethanol preci-
pitated, followed by ligation with R-Bgl adaptor cassettes (R-
Bgl-24: 5'-AGCACTCTCCAGCCTCTCACCGCA-3'; R-Bgl-12: 5'-
GATCT-GCGGTGA-3'). The ligation products were ampliﬁed
using the R-Bgl-24 as the primer (25 cycles of 1 min each at
958C and 3 min at 728C). Both tester and driver representations
were digested with Sau3AI to remove the R-Bgl adaptors. The
tester representations were then puriﬁed by gel ﬁltration chro-
matography (cDNA spun column, Amersham Pharmacia
Biotech) and then ligated to the J-Bgl adaptor (J-Bgl-24: 5'-
ACCGACGTCGACTATCCATGAACA-3'; J-Bgl-12: 5'-GATCTG-
TTCATG-3'). Two hundred nanograms of J-adaptor-ligated
tester DNA was mixed with 40 mg of the driver DNA, hybri-
dised for 21 h at 678C, and ampliﬁed by PCR with J-Bgl-24
as primer for 10 cycles. After digestion of single-stranded
DNA with Mung-bean nuclease (New England Biolabs, Inc.,
Beverly, MA, USA), additional PCR ampliﬁcation for 20–30
cycles with J-Bgl-24 was performed. The second competitive
hybridization was performed by switching to the N-Bgl adaptor
(N-Bgl-24: 5'-AGGCAACTGTGCTATCCGAGGGAA-3'; N-Bgl-12:
5'-GATCTTCCCTCG-3'). One hundred nanograms of ligation
solution were mixed with 20 mg of driver DNA. Denaturing,
reannealing, and selective ampliﬁcation of the self-annealed
product were performed as for the ﬁrst cycle. The ﬁnal PCR
products which removed the adaptor were ligated into pBlue-
script II that had been digested with BamHI (Toyobo
Biochemicals) and treated with calf intestinal alkaline phospha-
tase (Takara Biomedicals, Shiga, Japan). After transformation
of XL1Blue-competent cells, insert-positive plasmid clones were
selected by PCR ampliﬁcation of the inserts using T3 and T7
primers and restriction-digestion of the PCR products with
Sau3AI.
Sequencing analysis
DNA sequencing was performed on an ABI PRISM 310 Genetic
Analyzer (Perkin Elmer Applied Biosystems) using a BigDye
Terminator Cycle Sequencing FS Ready Reaction Kit (Perkin Elmer
Applied Biosystems). Sequencing data were analysed with BLAST
search program (http://www.ncbi.nih.gov/blast/blast.cgi) (Altschul
et al, 1990).
Northern blot analysis
Total RNAs were isolated using RNAzol (Tel-test, Inc., TX, USA)
and 10 microgram aliquots from prostate tissues were separated
by electrophoresis in 1% agarose-formaldehyde gel and trans-
ferred to nylon membranes (Hybond-N, Amersham Pharmacia
Biotech, UK). RDA clones inserted into pBluescript II and a
human glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
cDNA (Clontech, UK), employed as internal standard, were used
as the probes. Expression signals were quantitatively analysed
using a den-sitometer (ImageMaster, Amersham Pharmacia
Biotech).
DNA transfection
A human Lsm1 cDNA fragment including full open reading
frame was cloned into the pTarget mammalian expression
vector (Pro-mega, WI, USA). DNA transfection into PC3 cells
was carried out with a Lipofectin protocol (Life Technologies,
Inc. MD, USA). Stable transfectants were selected with
500 mgm l
71 G418 (Life Technologies, Inc.) and established by
ring cloning.
Cell proliferation assay
PC3 and its transfectants were maintained in F-12K medium (Life
Technologies, Inc.) containing 10% foetal bovine serum and incu-
bated at 378C under a humidiﬁed 5% CO2 atmosphere. Cells were
seeded into a 24-well plate at a density of 1610
4 cells per 2 ml
medium, and incubated for 3, 5 and 7 days. Live cells from each
culture were counted using Trypan blue staining. Each assay was
carried out at least in triplicate.
Chemoinvasion assay
A membrane invasion culture system was used to measure tumour
cell invasion (Albini et al, 1987; Hendrix et al, 1987). Sterile cell
culture inserts with 8 mm pore sized polyethylene terephthalate
ﬁlters (Becton Dickinson, NJ, USA) were coated with 100 mg base-
ment membrane Matrigel (Becton Dickinson), dried under laminar
ﬂow hood, and placed in 24-well plates ﬁlled with F-12K medium
containing 0.1% bovine serum albumin (BSA) and 10 mgm l
71
ﬁbronectin as a chemoattractant. Cells (1610
5), suspended in F-
12K containing 0.1% BSA, were seeded in cell culture inserts
and, after incubation at 378C for 24 h, the ﬁlters were ﬁxed in
80% ethanol and stained with Giemsa. Invaded cells were counted
under microscope at high power ﬁelds. Each assay was carried out
at least in quadruplicate.
Animals
Male KSN (nu/nu) nude mice, 5-weeks-old, were purchased from
Japan SLC, Inc. (Shizuoka, Japan). The animals were maintained
and treated in accordance with institutional guidelines and in
compliance with national and institutional law and politics. Cells
(1610
6) were inoculated into the subcutaneous tissues in their
ﬂanks. Tumour volume was calculated from the formula: tumour
volume=(width)
26length/2 (Osborne et al, 1985). Mice were killed
at 20 weeks for histological assessment of invasion or metastases of
tumour cells.
mRNA in situ hybridisation
A fragment of Lsm1 complementary DNA, corresponding to
nucleotides 434 to 582 of Lsm1 cDNA (Salgado-Garrido et al,
1999), was cloned into the vector pGEM-T (Promega, Madison,
WI, USA). Antisense and sense Lsm1 riboprobes were prepared
using pGEM-T/Lsm1 as the template and a digoxigenin RNA label-
ling kit (Roche Diagnostics). After deparafﬁnisation, sections were
treated with 3 mgm l
71 proteinase K for 20 min at 378C, and post-
ﬁxed in 4% paraformaldehyde for 10 min. The sections were then
placed in hybridisation buffer containing digoxigenin-labelled anti-
sense riboprobes for 16*18 h at 428C. After hybridisation, the
sections were washed in 26SSC/50% formamide for 30 min at
428C, then TNE buffer (10 mM Tris-HCl (pH 8.0), 500 mM NaCl,
1m M EDTA) for 10 min at 378C. Thereafter, the sections were
treated with 10 mgm l
71 of RNase (Roche Diagnostics) for
30 min at 378C. The slides were rinsed in buffer A (100 mM maleic
acid, 150 mM NaCl, pH 7.5) for 10 min, and then incubated with
buffer C (1% blocking reagent (Roche Diagnostics) dissolved in
buffer A). Horse-radish peroxidase conjugated sheep anti-digoxi-
genin Fab fragments (1:100, Roche Diagnostics) were applied for
30 min. The slides were then washed in buffer A followed by incu-
bation with biotinylated tyramide in ampliﬁcation diluent (NEN
Life Science Products, Inc., Boston, MA, USA) for 10 min, three
times in buffer A for 5 min and alkaline phosphate conjugated
streptoavidin (1:5000, Roche Diagnostics) for 30 min. After
sequential washing in buffer A containing 0.2% Tween 20 and
buffer B (100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 50 mM
MgCl2), hybridization signals were detected with 5-bromo-4-
chloro-3-indolyl-phosphate (BCIP)/4-nitro blue tetrazolium chlor-
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situ hybridisation was proven by parallel hybridisation of the
sections with sense riboprobes.
LOH analysis
LOH was examined by PCR ampliﬁcation of highly polymorphic
microsatellite repeat markers on chromosome 8p11.2, including
D8S1747, D8S416 and D8S1722, around Lsm1 gene. The order
of these loci has been determined by available human genome
sequencing data for 8p11.2 of the Japan Science Technology
Corporation (JST) (http://www-alis.tokyo.jst.go.jp/HGS/top.pl) to
be: D8S1722-Lsm1 gene-D8S416–D8S1747. PCR reactions were
performed with
32P-end-labelled primers for 35–45 cycles at
948C for 1 min, 568C for 1 min and 728C for 1 min in a 15 ml
volume. The PCR products were separated on 6% polyacrylamide
sequencing gels and used to expose X-ray ﬁlms. Allelic loss was
judged when a reduction in signal intensity of 450% in one allele
was evident in the tumour as compared to the paired normal
tissue.
Gene mutation analysis
The region covering Lsm1 coding sequences was ampliﬁed by PCR
in the presence of [a-
32P]dCTP. The PCR products were then
subjected to single-strand conformational polymorphism (SSCP)
analysis under two conditions (with or without 5% glycerol).
The primers used to PCR–SSCP analysis were as follows; 5'-
GCTGTGCATTGCAGCATTAT-3' and 5'-CGGGAGGAGATAAAC-
TA-3' for exon 1; 5'-AAGATTTTTTCCTCTCTCC-3' and 5'-GAG-
ATGTCCATAAATTAATA-3' for exon 2; 5'-GGTTTTTCCCTATA-
CACTT-3' and 5'-TACAGCAGCTTAATAGTTTTC-3' for exon 3;
5'-GAAGTTTTCAAACCTGTCTC-3' and 5'-CACTTTCAACTTCT-
CTGCTT-3' for forepart of exon 4; and 5'-AACAAAGGGTGGAA-
CAGCA-3' and 5'-AAGAGCCAACAGCCTCT-3' for the hind part
of exon 4.
Statistical analyses
Differences of the data for cell proliferation, chemoinvasion assay
and tumour volume of nude mice was statistically assessed by an
ANOVA test (Scheffe’s analysis).
RESULTS
Eleven genes were identiﬁed to be speciﬁcally down-regulated in
advanced prostate cancers by the cDNA-RDA method and all of
these were identical to known genes listed as follows; LIM protein
(GenBank Accession #AF061258), cytoplasmic dynein light chain 1
(U32944), small subunit of calpain (X04106), acylamino acid-
releasing enzyme (D38441), human X-box binding protein 1
(hXBP-1)(M31627), PRO1073 (AF113016), Lsm1 (AJ238094), 5-
aminoimidazole-4-carboxamide ribonucleotide formyltransferase/
inosine monophosphate cyclohydrolase (U37436), KIAA0088 gene
(D42041), prostasin (L41351) and thyroid hormone-binding
protein (J02783). On the other hand, all of seven genes up-regu-
lated in advanced cancers were unknown.
Among these, Lsm1 mRNA expression was detected by
Northern blot analysis in three of three normal prostates, four
of four organ-conﬁned prostate cancers and in LNCaP cells,
while no signals were found for three cases of advanced pros-
tate cancers, including primary sites and bone metastatic foci,
as well as DU145 and PC3 cells (Figure 1). Lsm1 mRNA
expression was detected in normal epithelial and adenocarcino-
ma cells in the human prostates by in situ hybridisation
(Figure 2). Lsm1 mRNA expression levels in LNCaP cells did
not alter with growth in medium lacking androgens (data not
shown).
Four stable PC3/Lsm1-transfectants (#14-1, #14-3, #15-1 and
#15-2) were established, which demonstrated no signiﬁcant differ-
ences in morphology or cell proliferation in comparison with
parent PC3 or PC3/mock-transfectants (Figures 3 and 4). In
contrast, signiﬁcant reduction of invasive potential of all Lsm1-
transfectants was observed in the Matrigel chemoinvasion assay
(Figure 4). Dihydrotestosterone did not affect the growth of
Lsm1-transfectants (data not shown).
Three out of four transfectants were able to form tumour masses
in implantation sites of nude mice. The average time for tumour
formation with the #15-1 transfectant was about 17 weeks while
with the other transfectants (#14-1, #15-2) it was about 5 weeks.
There were no obvious differences in the tumour volumes of each
cells. Lymph node metastasis was reduced in #15-1 and #15-2
(Table 1). The transfectant #14-1 showed lymph node metastases
(three out of ﬁve mice) and marked reduction of Lsm1 gene
expression in these metastatic foci and the primary tumours
(implantation site) on in situ hybridization. The ﬁnding suggested
that Lsm1 expression ceased in the #14-1 transfectant during the
course of proliferation at the implantation site.
D8S1747 and D8S416 markers were demonstrable located 700
and 350 kbp, respectively, downstream of the Lsm1 gene, while
D8S1722 was present 120 kbp upstream of the gene. Almost all
of the informative prostatectomised cases without neoadjuvant
therapy showed allelic retention of D8S1747, D8S416 and
D8S1722 loci, except for one lymph node metastatic focus (case
#M129), whereas refractory cancers frequently showed allelic loss
of these marker loci (Figures 5 and 6).
The available nucleotide sequence information of the GenBank
accession number AP000065 and the data from LA (long and accu-
rate) – PCR analysis for the intron 1 sequence revealed that Lsm1
is formed of four coding exons and three intervening introns span-
ning an area of 13100 bp of genomic sequence on chromosome
8p11.2. The intron/exon splice sites and their ﬂanking sequences
are in agreement with the consensus splicing signals (Iida, 1990).
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Figure 1 Northern blot analysis of human prostate total RNAs. Lanes 1
to 3, normal prostate tissues; lanes 4 to 7, organ-conﬁned cancers from
prostatectomized cases; lanes 8 to 10, refractory cancers from autopsy
cases, Pr: primary site, B: metastatic focus to the bone; lane 11, DU145; lane
12, LNCaP; lane 13, PC3. Each lane was loaded with 10 mg of total RNA.
Figure 2 Lsm1 mRNA expression in serial sections of a prostate adeno-
carcinoma. (a) H&E. In situ hybridization with antisense (b) and sense (c)
probes.
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region of Lsm1 in 46 prostate cancer cases examined, including
localized and refractory cases, by PCR–SSCP analysis.
DISCUSSION
Lsm1 was ﬁrst isolated from human pancreatic cancers as an up-
regulated gene and termed cancer-associated Sm-like protein
(Casm) (Schweinfest et al, 1997). Subsequently, Salgado-Garrido
et al (1999) identiﬁed that Casm gene is identical to Lsm1 (like
Sm protein 1). Eight Lsm proteins, Lsm1–Lsm8, have so far been
reported in humans (Achsel et al, 1999; Salgado-Garrido et al,
1999). Seven of these, Lsm2–Lsm8, have been shown to interact
with U6 snRNA and facilitate formation of U4/U6 RNA duplexes
(Achsel et al, 1999). Recent reports demonstrated that yeast
Lsm1 protein affects mRNA metabolism, particularly mRNA
decapping and degradation (Boeck et al, 1998; Tharun et al,
2000) and it is possible that human Lsm1 regulates some speciﬁc
genes related to tumour invasion or metastasis in prostate cancer
cells. Further investigations are needed to clarify the molecular
mechanisms of suppression of metastasis related to overexpression
of the Lsm1 gene.
Although the number of samples was small and the quality of
RNAs from refractory cancers due to sampling at autopsy was
problematic, it is clear from the present transfection study that
down-regulated expression of Lsm1 gene located at 8p11.2 is inti-
mately involved in invasive and metastatic ability of human
prostate cancers. The possible presence of putative tumour
suppressor or metastasis suppressor genes in chromosome 8p11.2
in prostate cancers has been pointed out by several authors
(Macoska et al, 1995; Crundwell et al, 1996; Prasad et al, 1998).
Deletion of chromosome 8p11.2 has been frequently found in
malignancies including stomach (Baffa et al, 2000), kidney (Schul-
lerus et al, 1999), urinary bladder (Choi et al, 2000) and colorectal
cancers (Chughtai et al, 1999), suggesting that Lsm1 gene is a
candidate tumour suppressor or metastasis suppressor gene in
common for a variety of human neoplasms.
The ﬁndings of a close association between down-regulation of
Lsm1 and prostate cancer progression and the fact of abundant
expression of Lsm1 in LNCaP but not in PC3 cells appear in
conﬂict with the data reported by Schweinfest et al (1997). They
also demonstrated diverse expression levels in many cancer cell
lines. Regarding the two discrepancies, a possible cause of the
former might be tissue-type speciﬁc Lsm1 expression. We have
no explanation for the latter.
KAI1, a metastasis suppressor gene and a member of the
membrane glycoprotein family, has been mapped to chromosome
11p11.2 and is known to contribute to metastasis of prostate
cancer through down-regulation without gene mutations (Dong
et al, 1995, 1996). Data on allelic loss of KAI1 region in prostate
cancers are, however, conﬂicting, and it has been demonstrated
that LOH is infrequent in American patients (Dong et al, 1996),
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Figure 3 Establishment of PC3/Lsm1-transfectants. (a) Total RNAs
were extracted from PC3, mock and Lsm1-transfectants and analysed for
Lsm1 levels by Northern blotting. (b) Morphology of PC3 and transfectant
cells. PC3 (a), mock1 (b), mock2 (c), Lsm1/14-1 (d), Lsm1/14-3 (e),
Lsm1/15-1(f) and Lsm1/15-2 (g).
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Figure 4 Data for cell growth and chemoinvasion assays of Lsm1-transfectants (means+s.d.). *Signiﬁcantly different from the values for PC3, mock1 or
mock2 at P50.001.
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Table 1 Characteristics of PC3/Lsm1-transfectants transplanted in nude mice
No. of Tumour volume
Metastasis/invasion
Cells mice Tumorigenicity (cm
3) Lymph node Vertebra
PC3 9 9 4.19+3.06 7 2
Mock 1 5 5 2.65+1.93 5 0
Mock 2 5 5 4.54+2.90 3 1
Lsm1/14-1 5 5 5.51+2.28 3 0
Lsm1/14-3 5 0 – 0 0
Lsm1/15-1 5 4 0.57+0.78 0 0
Lsm1/15-2 5 5 3.56+2.27 0 0
D8S1747
D8S416
D8S1722
M129 N113 N221 N303 N677
NB L i NB L i NPB
NPB
NPB NB
NB
NP L N
Figure 5 Autoradiograms illustrating the allelic losses on chromosome 8p11.2 in prostate cancers. Arrowheads indicate allelic loss. The primer sequences
used were 5'-CCACCTCTGATATGCCAATCAAG-3'/5'-TGGTTTCCTAAAACTTCACCCG-3' for D8S1747, 5'-GAGAATCGCTGGAACAGA-
GAAGG-3'/5'-GGCAGAGCTACCAAGAAACCAAAC-3' for D8S416 and 5'-CCTTGCTGGGAATTGTG-3'/5'-AGCTGCCTGGCTAAGAG-3' for
D8S1722. N, normal tissues; P, primary site; LN, lymph node metastasis; B, bone metastasis; Li, liver metastasis.
D8S1747
D8S416
Lsm1
D8S1722
Telomere Prostatectomized cases
without neoadjuvant therapy
Autopsy cases
(refractory cancer)
Stage B Stage C Stage D
Centromere
Loss of one allele;             retention of both alleles
Figure 6 Summary of LOH for polymorphic markers surrounding the Lsm1 gene on chromosome 8p11.2 in a series of prostate cancers. P, primary site;
LN, lymph node metastasis; Liver, liver metastasis; Bone, Bone metastasis. No mark indicates not informative. Numbers following the individual sample
number represent their Gleason’s score.
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of CD44 is also a candidate metastasis suppressor gene located on
chromosome 11p13, with potential involvement in prostate cancer
progression through decreased expression (Gao et al, 1997). The
present results demonstrated that Lsm1 suppressed prostate cancer
metastasis through down-regulation, similar to the cases with the
known metastasis suppressors, KAI1 or CD44, and we can specu-
late that the mechanism of decreased expression of this gene is
reduction of gene dosage by allelic loss.
cDNA–RDA is a powerful and highly efﬁcient method for iden-
tiﬁcation of differentially expression of genes between two mRNA
populations. However, it has limitations for enrichment of all
differentially expressed genes during the procedure because of
preferential ampliﬁcation of some messages and the lack of Sau3A1
restriction sites in cDNAs. This might explain why genes known to
be differentially expressed in advanced prostate cancer, such as
KAI1 or CD44, were not isolated in the present study.
As shown in Figure 1, Lsm1 was here found to be expressed in
LNCaP cells but not in PC3 and DU145 cells. These results suggest
that Lsm1 expression may contribute to acquisition of the andro-
gen-independent phenotype during prostate cancer progression.
The lack of androgen receptors is the major cause of androgen-
independency in PC3 and DU145 cells, with two factors thought
to contribute the loss of androgen receptor expression; methylation
of androgen receptor promoter and relative deﬁciency of transcrip-
tion factors (Chlenski et al, 2001). As described above, Lsm1 might
be involved in regulating some transcription factors related to
androgen receptor expression but it may not interfere with the
control of methylation levels in the promoter region. Hence it
may be that overexpression of Lsm1 alone was not able to render
PC3 cell androgen-dependent. The ﬁnding of high expression in
LNCaP cells, which are derived from a lymph node metastasis,
appears to contradict the conclusion of Lsm1 being a metastasis
suppressor gene. However, an explanation for this may lie with
alteration of the genes which are regulated by Lsm1. In fact, several
genes have been identiﬁed to ﬂuctuate with overexpression of Lsm1
using cDNA expression arrays (data not shown). Therefore, clariﬁ-
cation of the signalling cascade regulated by Lsm1 may contribute
to elucidation of the molecular mechanisms responsible for acqui-
sition of metastatic ability in human prostate cancers.
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